

This notice in TED website: <http://ted.europa.eu/udl?uri=TED:NOTICE:305308-2018:TEXT:EN:HTML>

**United Kingdom-Runcorn: Pharmaceutical products
2018/S 134-305308**

Contract award notice

Results of the procurement procedure

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1) Name and addresses

The NHS Commissioning Board (Operating Under the Name of NHS England)
2nd Floor, Rutland House
Runcorn
WA7 2ES
United Kingdom
E-mail: philip.grieve@nhs.net
NUTS code: UK

Internet address(es):

Main address: <https://nhsengland.bravosolution.co.uk>

I.2) Information about joint procurement

The contract is awarded by a central purchasing body

I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title:

NHS Framework Agreement for the supply of Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema
Reference number: CM/PHS/15/5500

II.1.2) Main CPV code

33600000

II.1.3) Type of contract

Supplies

II.1.4) Short description:

NHS Framework Agreement for the supply of Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema. The Framework Agreement is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland. The framework may also

be used by private sector contractors and agents working on behalf of the above. The framework will commence on the 1.7.2018 for a period of 12 months until 30.6.2019, with options to extend up to a further 36 months. Please refer to the invitation of Offer documents for the list of Purchasing Points.

II.1.6) **Information about lots**

This contract is divided into lots: no

II.1.7) **Total value of the procurement (excluding VAT)**

Value excluding VAT: 72 000 000.00 GBP

II.2) **Description**

II.2.1) **Title:**

II.2.2) **Additional CPV code(s)**

33141510

33141520

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points

II.2.4) **Description of the procurement:**

NHS Framework Agreement for the supply of Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema. The framework agreement is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland. The framework may also be used by private sector contractors and agents working on behalf of the above. The framework will commence on the 1.7.2018 for a period of 12 months until 30.6.2019, with options to extend up to a further 36 months. Please refer to the invitation of Offer documents for the list of Purchasing Points.

II.2.5) **Award criteria**

Cost criterion - Name: Price / Weighting: 70 %

Cost criterion - Name: Security of Supply / Weighting: 20 %

Cost criterion - Name: ease of use / Weighting: 10 %

II.2.11) **Information about options**

Options: no

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

Section IV: Procedure

IV.1) **Description**

IV.1.1) **Type of procedure**

Open procedure

IV.1.3) **Information about a framework agreement or a dynamic purchasing system**

The procurement involves the establishment of a framework agreement

IV.1.6) **Information about electronic auction**

IV.1.8) **Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

IV.2) **Administrative information**

IV.2.1) **Previous publication concerning this procedure**

Notice number in the OJ S: [2018/S 039-084689](#)

IV.2.8) **Information about termination of dynamic purchasing system**

IV.2.9) **Information about termination of call for competition in the form of a prior information notice**

Section V: Award of contract

Contract No: CM/PHS/15/5500

Title:

NHS Framework Agreement for the supply of Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema

A contract/lot is awarded: yes

V.2) **Award of contract**

V.2.1) **Date of conclusion of the contract:**

20/06/2018

V.2.2) **Information about tenders**

Number of tenders received: 3

Number of tenders received from SMEs: 1

The contract has been awarded to a group of economic operators: no

V.2.3) **Name and address of the contractor**

CSL Behring (UK) Ltd

Haywards Heath

RH16 1AH

United Kingdom

NUTS code: UK

The contractor is an SME: no

V.2.4) **Information on value of the contract/lot (excluding VAT)**

Total value of the contract/lot: 1.00 GBP

V.2.5) **Information about subcontracting**

Section V: Award of contract

Contract No: CM/PHS/15/5500

Title:

NHS Framework Agreement for the supply of Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema

A contract/lot is awarded: yes

V.2) **Award of contract**

V.2.1) **Date of conclusion of the contract:**

20/06/2018

V.2.2) **Information about tenders**

Number of tenders received: 3

Number of tenders received from SMEs: 1

The contract has been awarded to a group of economic operators: no

V.2.3) **Name and address of the contractor**

Pharming Group NV

Northampton
United Kingdom
NUTS code: UK
The contractor is an SME: yes

V.2.4) **Information on value of the contract/lot (excluding VAT)**

Total value of the contract/lot: 1.00 GBP

V.2.5) **Information about subcontracting**

Section V: Award of contract

Contract No: CM/PHS/15/5500

Title:

NHS Framework Agreement for the supply of Icatibant and C1 esterase products for the treatment of Hereditary Angioedema

A contract/lot is awarded: yes

V.2) **Award of contract**

V.2.1) **Date of conclusion of the contract:**

20/06/2018

V.2.2) **Information about tenders**

Number of tenders received: 3

Number of tenders received from SMEs: 1

The contract has been awarded to a group of economic operators: no

V.2.3) **Name and address of the contractor**

Shire Pharmaceuticals Ltd
London
United Kingdom
NUTS code: UK
The contractor is an SME: no

V.2.4) **Information on value of the contract/lot (excluding VAT)**

Total value of the contract/lot: 1.00 GBP

V.2.5) **Information about subcontracting**

Section VI: Complementary information

VI.3) **Additional information:**

VI.4) **Procedures for review**

VI.4.1) **Review body**

The NHS Commissioning Board (operating under the name of NHS England)
Runcorn
United Kingdom

VI.4.2) **Body responsible for mediation procedures**

VI.4.3) **Review procedure**

VI.4.4) **Service from which information about the review procedure may be obtained**

VI.5) **Date of dispatch of this notice:**

12/07/2018